Crain's Cleveland article features CytoCore's new products licensed from University Hospitals Cleveland; Dr. Gorodeski Hopeful New Biomarker Will Develop into Annual Screen for Uterine Cancer.

CHICAGO -- CytoCore, Inc. (OTCBB: MCDG) today announced that it is featured in an article in Crain's Business Week Cleveland.

CrainsCleveland

University Hospitals, Chicago biz team to test cancer screening tools

By SHANNON MORTLAND

6:00 a.m., March 6, 2006

As a gynecologist at University Hospitals of Cleveland, Dr. George Gorodeski has dedicated his career to women's health. Now he's teaming with a Chicago company in hopes of turning two of his discoveries into tools that will enable women to be treated faster and better.

Dr. Gorodeski is working with CytoCore Inc., which develops cancer screening systems, to conduct clinical trials on two potential inventions -- a biomarker that would distinguish between pre-cancerous and cancerous cells in the uterus, and a drug delivery system for the cervix.

CytoCore is raising $2 million in private money to foot the bill for the clinical trials, which Dr. Gorodeski said likely would begin within three months. Gene Martineau, director of communications at CytoCore, said his firm hopes to attract companies to help pay for the trials.

By not applying for research grants from the National Institutes of Health, clinical trials can begin faster and, if successful, the products can be taken to market quicker, said Stephen Behm, a consultant who is working with UH to help commercialize its discoveries. The products would be licensed to CytoCore.

Though Dr. Gorodeski cautions that much work needs to be done before the products can be proven successful and be put on the market, he said preliminary data on the biomarker shows it could be a promising means of detecting cervical and endometrial cancers in women.

If the clinical trials produce good results, Dr. Gorodeski said he hopes to develop the biomarker into an annual test that would screen the lining of the uterus for cancer. Such screening now is not performed on women as part of their annual exams, said Dr. Gorodeski, who also is a professor of reproductive biology, oncology, physiology and biophysics at Case Western Reserve University.

"The costs of not finding the disease early on are much greater than going through the screening once a year," he said.

Dr. Gorodeski also is working on a more effective way to treat problems such as endometrial and cervical cancer. With CytoCore's help, he'll study the development of a device that would be affixed directly to the cervix to deliver medication to the cancerous area.

"It would target only the cervix, not the adjacent organs," Dr. Gorodeski said. "It could be important to patients who are at risk for developing high-grade cervical dysplasia and cervical cancer."

UHC's Mr. Behm said the medicine delivered by the device still would be considered chemotherapy, but it wouldn't be injected into the bloodstream, as is usually the case. Therefore, other parts of the body would not be inflicted with chemicals, which means patients wouldn't experience the side effects often associated with cancer treatment, he said.

Dr. Gorodeski's inventions are the latest from UH, which in the last year has become more active in helping doctors identify treatment ideas that could be marketed.

And there are plenty more inventions in the works.

"We plan on having more things like this to talk about," Mr. Behm said.

Sign up for free e-mail alerts about breaking business news: http://www.crainscleveland.com/register

Copyright (c) 2006, by Crain Communications Inc. All rights reserved.

About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening and treatment system that can be integrated into existing medical models or at the point-of-care. More information is available at www.Molecular-Dx.com.

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2004, and its Quarterly Reports on Form 10-QSB for the quarters ended June 30, 2005, and September 30, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.